Guo, R., Yang, G., Feng, Z., Zhu, Y., Yang, P., Song, H., Wang, W., Huang, P., and Zhang, J., Biomater
To be considered successful, no antibodies will need to be customized, multifaceted, or targeted to an individuals neoantigen repertoire, while also overcoming or reducing the immunosuppressive burden of the tumor microenvironment
Below is a framework comparing safety considerations across common administration scenarios to help inform discussions with your healthcare provider
Just one quick shot can help
The most commonly reported side effects in retatrutide clinical trials have been gastrointestinal, including nausea, vomiting, diarrhea, constipation, abdominal discomfort, and decreased appetite